Global Coronavirus (COVID-19) Treatment Market is valued approximately USD XX billion in 2019 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2020-2026. The COVID-19 outbreak triggered owing to Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), which is affecting millions of citizens worldwide. According to the World Health Organization, SARS-CoV-2 has spread to over 209 countries and territories with over as of 20th April 2020, 2,314,621 confirmed coronavirus cases were recorded with 157,847 deaths globally. The sudden epidemic of this extremely contagion disease has the increased the revenue of the pharmaceutical industry and propelling the industry to perform more than their unique production capacity. The major pharmaceutical companies are highly involved in the R&D activities for developing preventive interventions and therapeutic medicine. Exponentially growing incidents worldwide necessitating short- and long-term respiratory support and multiple collaborations for the development of medications for COVID-19 with ongoing clinical trials are some of the key factors likely to drive the market over the forecast period. For instance, the United States National Institute of Health (NIH) has initiated COVID-19 vaccine trial on 16 March 2020. Similarly, on February 2020, Gilead Sciences is assessing a drug, remdesivir, a nucleoside analog presently in phase 3 clinical trial for the treatment of COVID-19.

The regional analysis of global Coronavirus (COVID-19) Treatment market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to owing to high number of COVID-19 cases in the United States which require rapid number of testing in the near future to contain the spread of disease in the region. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2026. Factors such as owing to large scale of population base in the countries such as India and China, rapid growth in number of coronavirus infected cases would create lucrative growth prospects for the Coronavirus (COVID-19) Treatment market across Asia-Pacific region.

Major market player included in this report are:
Moderna Therapeutics
Inovio Pharmaceuticals, Inc.
Clover Biopharmaceuticals
ExpreS2ion Biotechnologies ApS
CanSino Biologics, Inc.
Greffex Inc.
Altimmune
Janssen Pharmaceuticals
Ascletis Pharma Inc.
Bravovax,

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
Disease treatment drugs
Preventive vaccines.

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2016, 2017, 2018
Base year - 2019
Forecast period - 2020 to 2026

Target Audience of the Global Coronavirus (COVID-19) Treatment Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors